Refractory myelodysplastic syndrome/acute myeloid leukemia

Clinical trials for Refractory myelodysplastic syndrome/acute myeloid leukemia explained in plain language.

Never miss a new study

Get alerted when new Refractory myelodysplastic syndrome/acute myeloid leukemia trials appear

Sign up with your email to follow new studies for Refractory myelodysplastic syndrome/acute myeloid leukemia, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1 Not yet finished but already full! 1

Experimental drug TAK-243 targets tough blood cancers in early trial

Disease control Ongoing

This early-phase study is testing a drug called TAK-243 in people whose acute myeloid leukemia or myelodysplastic syndrome has come back or is not responding to treatment. The goal is to find the best dose and check for side effects. The trial is currently on hold.

Matched conditions: REFRACTORY MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA

Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Sep 18, 2026 00:00 UTC

Refractory myelodysplastic syndrome/acute myeloid leukemia

Get alerted when new Refractory myelodysplastic syndrome/acute myeloid leukemia trials appear

Experimental drug TAK-243 targets tough blood cancers in early trial